Merck

Variational AI is a preclinical therapeutics company that leverages advanced machine learning techniques to efficiently generate novel compounds optimized for various properties, thereby addressing common challenges in drug development. The company focuses on creating selective kinase inhibitors for solid tumors while also exploring additional target classes. By collaborating with leading biopharmaceutical partners, Variational AI aims to streamline the drug discovery process, enabling these partners to conduct multi-property molecular optimization. This approach significantly reduces the time needed to identify drug-like molecules with a higher likelihood of success in clinical trials. In addition to its collaborations, Variational AI is also developing its own internal pipeline of therapeutic candidates.

HD is a healthcare and surgery marketplace, powering over 1,500+ healthcare providers including some of the biggest hospitals. HD connects patients to hospitals, clinics, operating rooms, and surgeons while offering healthcare financing solutions to increase access to affordable care and surgeries. To date, over 250,000 patients have benefited from more accessible and affordable healthcare and surgeries through the company's platform.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

Modifi Biosciences is a leader in direct DNA modification and the development of novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drug development methods.

Ash is a leading at-home health testing platform expanding care to reach those most in need. Working closely with our partners, we tailor end-to-end testing solutions that meet the unique needs of any health organization’s population. Our strength comes from our unmatched understanding of people—whether that means learning the best ways to reach them or innovating a new way to keep them connected and cared for. We use our deep knowledge to develop field-tested best practices that engage hard-to-reach patients and members where they are. Because when people come first, better health outcomes are possible for all.

Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

CargoSense provides data driven logistics to the healthcare industry utilizing a disruptive business model. The company provides a solution that serves as the "black box" for logistics shipments for highly sensitive goods such as pharmaceuticals, food and machinery. The company combines a data and analytics SaaS (Software as a Service), iOS-based Apps and the latest Bluetooth sensors delivered as a managed service to its customers. The company uses data and analytics to give insight into everything customer's shipments experience. This goes beyond temperature monitoring and excursions to total visibility of how transportation providers are treating goods. Customers gain compliance with government regulation, lower shipping costs and a reduction in product loss.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Friends of Puerto Rico is a nonpartisan, non-profit social impact group that advocates for economic growth. and education through result-oriented entrepreneurial ventures centered on sustainability and self-sufficiency.

Atropos Health is a technology company based in Palo Alto, California, founded in 2019. It specializes in developing a digital prognostogram platform, known as the Atropos Evidence Platform, which transforms health data into actionable real-world evidence. By integrating electronic medical record (EMR) data, the platform generates digital evidence tailored to individual patient outcomes. This enables healthcare institutions, life science companies, and researchers to utilize previously siloed EMR data effectively. The platform aims to close evidence gaps in healthcare, enhance clinical outcomes through data-driven care, and accelerate research initiatives. Atropos Health serves caregivers, healthcare organizations, and risk-bearing entities, contributing to advancements in evidence-based healthcare.

N-Power Medicine specializes in drug development and clinical research.

Abceutics operates as a biopharmaceutical company.

Baseimmune is a biotech startup focused on developing the next generation of vaccines. The company has created a platform for pathogen analysis that facilitates the design of antigens and vaccines. Utilizing advanced technology, Baseimmune's platform enables the generation of antigens with a high level of informatics depth, allowing for effective responses to emerging and challenging pathogens. This capability ensures that healthcare providers can maintain vaccine efficacy even in the face of pathogen mutations.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets. Unnatural Products was founded in 2017 and is headquartered in Santa Cruz, California.

Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

AeroSafe Global specializes in providing cold chain management services focused on temperature-sensitive shipping for the pharmaceutical and biopharmaceutical industries. The company develops and produces aerogels and related materials, ensuring effective thermal insulation for the transportation of biomedical products. AeroSafe Global offers customized solutions that incorporate proprietary packaging and logistics, aiming for zero temperature excursions during transit. By utilizing a packaging technology reuse model along with data tracking and analytics, the company supports its clients in delivering temperature-sensitive drugs and medical devices safely and sustainably. Its commitment to reliable supply chain solutions has made AeroSafe Global a trusted partner for leading biopharma companies.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Prometheus Biosciences, formerly known as Prometheus Laboratories, is a specialty pharmaceutical company headquartered in San Diego, California. The company develops and commercializes innovative pharmaceutical and diagnostic products aimed at enhancing individualized patient care, particularly in the fields of gastroenterology and autoimmune diseases. Prometheus offers a range of diagnostic tests, including assays for monitoring drug and anti-drug antibody levels, as well as tests for inflammatory bowel disease and celiac disease. Among its marketed products are Entocort EC, indicated for Crohn's disease, and Imuran, used in kidney transplantation and rheumatoid arthritis management. Additionally, the company is involved in developing new treatments, such as COLAL-PRED, for gastrointestinal disorders. Through its advanced diagnostics and therapeutic offerings, Prometheus Biosciences assists healthcare providers in optimizing treatment strategies and improving patient outcomes.

Mamotest is a company focused on improving breast cancer outcomes through a digital platform that leverages artificial intelligence. By democratizing access to early diagnosis and patient guidance, Mamotest aims to transform the care delivery process. The platform employs telediagnosis and ensures complete traceability of the patient journey, promoting a proactive approach to health rather than a reactive one. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

TransVoyant is an IT company streaming and analyzing IoT and big data for the supply chain and digital supply chain. The company collects, cleanses, and constantly updates one of the repositories of real-time big data over one trillion events each day. By applying advanced machine learning algorithms to these real-time data streams, TransVoyant gives leading companies and government organizations a live global picture of their static and moving assets, as well as predictive insights that enable them to anticipate and avoid threats and disruptions resulting from a multitude of internal and external factors such as weather, port congestion, natural disasters, supplier failure, road construction, competitor behavior, and labor strikes, to name a few. TransVoyant was founded in 2011 and is headquartered in Alexandria, Virginia, United States.

Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

CancerIQ is a precision health technology company that provides a platform designed to assist healthcare providers in identifying and managing patients at high risk for cancer. The platform features predictive analytics and screening tools to help clinicians detect at-risk patients early. It includes a comprehensive library of evidence-based guidelines and risk models, which aids providers in interpreting data and guiding patients toward appropriate genetic testing, screening, and treatment interventions. Additionally, CancerIQ offers a digital genetic test ordering system and patient management tools, enhancing clinician efficiency and improving patient outcomes by facilitating early cancer detection and adherence to evidence-based care strategies.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

TagNTrac is an IoT platform that provides integrating multimode technologies typically hardware, software, and data to build solutions.

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Mamotest is a company focused on improving breast cancer outcomes through a digital platform that leverages artificial intelligence. By democratizing access to early diagnosis and patient guidance, Mamotest aims to transform the care delivery process. The platform employs telediagnosis and ensures complete traceability of the patient journey, promoting a proactive approach to health rather than a reactive one. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates.

M2Gen is a health informatics solutions company established in 2006 at the Moffitt Cancer Center in Tampa, Florida. The company specializes in advancing precision medicine by integrating and analyzing clinical and molecular data. Its integrated platform helps identify patient susceptibility to diseases, predict drug responses, and match patients with optimal therapies for better treatment outcomes. M2Gen also offers a portfolio designed for biopharmaceutical companies to discover new targets and biomarkers, enhance clinical trial design and enrollment, and conduct post-market analysis. One of its key initiatives is the Total Cancer Care Protocol, which studies patients throughout their lifetime, and the ORIEN Avatar Research Program, which focuses on individuals with advanced disease and limited treatment options. M2Gen operates as a subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

Zapata Computing, Inc. is a quantum software company that specializes in developing computing solutions for various industries, including finance, healthcare, logistics, and pharmaceuticals. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company offers Orquestra, a software platform that enables users to compose quantum workflows and execute them on both quantum and classical hardware. This platform facilitates simulations, optimizations, and machine learning applications, allowing for efficient management of complex tasks across different environments. As a spin-out from Harvard University, Zapata Computing leverages advanced computational techniques grounded in quantum physics to provide hardware-agnostic solutions tailored to enterprise organizations.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

Volansi, Inc. is a logistics and transportation company that specializes in the manufacture of heavy-payload drones for various sectors, including commercial, defense, and humanitarian applications. Founded in 2015 and headquartered in Concord, California, Volansi designs and operates unmanned aerial vehicles to facilitate time-critical deliveries over long distances. The company targets industries such as construction, oil and gas, mining, and healthcare, providing on-demand and point-to-point shipment solutions. Its drones are engineered to deliver goods along fixed routes, addressing specific challenges related to time and cost, thereby enabling enterprises to optimize their logistics and improve operational efficiency.

AeroSafe Global specializes in providing cold chain management services focused on temperature-sensitive shipping for the pharmaceutical and biopharmaceutical industries. The company develops and produces aerogels and related materials, ensuring effective thermal insulation for the transportation of biomedical products. AeroSafe Global offers customized solutions that incorporate proprietary packaging and logistics, aiming for zero temperature excursions during transit. By utilizing a packaging technology reuse model along with data tracking and analytics, the company supports its clients in delivering temperature-sensitive drugs and medical devices safely and sustainably. Its commitment to reliable supply chain solutions has made AeroSafe Global a trusted partner for leading biopharma companies.

Zapata Computing, Inc. is a quantum software company that specializes in developing computing solutions for various industries, including finance, healthcare, logistics, and pharmaceuticals. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company offers Orquestra, a software platform that enables users to compose quantum workflows and execute them on both quantum and classical hardware. This platform facilitates simulations, optimizations, and machine learning applications, allowing for efficient management of complex tasks across different environments. As a spin-out from Harvard University, Zapata Computing leverages advanced computational techniques grounded in quantum physics to provide hardware-agnostic solutions tailored to enterprise organizations.

Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.

Preventice Solutions, Inc. specializes in mobile cardiac health solutions and digital healthcare software aimed at improving patient management. Founded in 2007 and headquartered in Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas, the company offers a range of services and devices designed to facilitate real-time patient monitoring. Its PatientCare Portal allows healthcare providers to independently manage and interpret patient data through a self-managed cloud-based platform. Additionally, the PatientView and PatientFlow Portals serve healthcare organizations and monitoring centers, respectively. Preventice Solutions also provides innovative wearable devices, such as the BodyGuardian Heart, a compact monitor promoting patient mobility and data collection, and the BodyGuardian Verité, a dual-modality remote cardiac sensor. These solutions enable precise identification and management of cardiac issues, ultimately connecting patients, clinicians, and healthcare facilities for enhanced care.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing applications and games aimed at managing chronic health conditions and improving patient adherence. Established in 2008, Ayogo employs behavioral psychology and social gaming principles to enhance health outcomes, serving a diverse clientele that includes insurers, healthcare providers, and pharmaceutical companies. The company's flagship product, GoodLife, is a customizable platform featuring gamification elements, incentives, and social interaction, while its suite of Alternate Reality Games integrates online and real-world experiences to facilitate learning. Ayogo's platform is designed to tailor content and support to individual psychosocial factors, promoting patient engagement by fostering activation and adherence to therapy. With a collaborative approach involving patients and clients, Ayogo emphasizes thoughtful innovation within its creative studio environment.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

She’s Well brings a Netflix-like subscription model to fertility, to help women, men, and couples to have children when they’re ready. The company works with its network of top-tier fertility centers to provide financing plans for fertility testing, IVF, egg freezing and sperm freezing. With an on-demand concierge care approach, She’s Well provides support and guidance, to make the fertility journey less confusing and isolating. 1 in 6 couples has trouble conceiving and we’re waiting longer to try. Women increasingly delay childbirth - one in three women in the U.S. has her first child after 30 and one in ten after 35. Male sperm count has decreased over 50 percent in the last decade. Despite all the solutions available on the market, infertility services remain available to only 1%. Health plans usually don't cover infertility treatments. The typical costs range from 12,000 to 20,000 dollars for IVF, plus another few thousand for the genetic testing involved to ensure the fetus is chromosomally normal. To help, She’s well started out offering subscription plans and concierge guidance to make fertility care more affordable and accessible to the 99%. We need to usher a world where decisions about family and career aren't ruled by biological clocks and where the best options, science, and care are available to everyone who wants to start a family.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

CIOX Health, LLC was a healthcare information management company based in Alpharetta, Georgia, specializing in the provision of healthcare information and clinical data services. The company developed a cloud-based platform designed to enhance healthcare outcomes by transforming shared healthcare information. Its offerings included information release, record retrieval, coding and education, clinical abstraction, and risk adjustment solutions. Additionally, CIOX provided AudaPro, an audit tool aimed at centralizing processes within the healthcare sector. The company served a diverse clientele, including healthcare providers, health plans, government agencies, and legal firms. In 2021, CIOX Health merged with Datavant, and the combined entity now operates under the Datavant name.

Tilos Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in creating anti-LAP antibodies that target the Latency Associated Peptide of TGF beta, which plays a critical role in regulating immune responses. Tilos Therapeutics primarily concentrates on modulating regulatory T cells and effector cells to enhance the immune system's ability to combat diseases. By leveraging these immunological pathways, Tilos aims to provide innovative treatments that enable patients to initiate therapy more rapidly, ultimately leading to improved medical outcomes.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, specializing in the development of therapeutics that target bone-related diseases. The company utilizes a unique prodrug platform that delivers bi-specific small-molecule therapeutics selectively to bone tissue, minimizing side effects associated with systemic exposure. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic, designed to potentially reverse bone loss linked to conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary technology overcomes the challenges of delivering medications to the difficult-to-treat bone environment, which often requires high drug doses and can lead to significant side effects. Through pre-clinical in-vivo models, the effectiveness of this bone-targeting system has been confirmed, positioning Mesentech to address various low-bone-density disorders and enhance bone healing outcomes. The company was incorporated in 2013 and continues to innovate in the field of bone therapeutics.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

TriNetX, Inc. operates a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a suite of solutions, including TriNetX Live for analyzing patient populations and TriNetX Research for accessing longitudinal clinical data. Its platform integrates electronic medical records and clinical documentation, enabling users to optimize clinical trial design, improve site selection, and accelerate recruitment processes. Additionally, TriNetX offers tools such as Natural Language Processing for extracting clinical facts and specialized resources for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX has expanded its presence internationally with offices in Sydney, London, and Sao Paulo. The platform is designed to be compliant with HIPAA and GDPR regulations, ensuring the secure handling of sensitive health data.

Clinithink, a London, UK-based healthcare software company. Led by CEO Chris Tackaberry, Clinithink has developed cloud-based text processing capability that can be used to support data analytics, coding and decision support in healthcare applications. Its patent-pending Clinical Language Indexing software (CLiX) uses Natural Language Processing (NLP) to construct coded output from physicians’ notes using industry data standards (ICD-9, ICD-10, and SNOMED CT).

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Kytopen is a developer of a cell therapy platform that focuses on the non-viral delivery of molecules into challenging immune cells. The company's innovative technology integrates microfluidics and automation to streamline the delivery process, making it faster, easier, and more cost-effective. Kytopen's automated cell engineering platform enables researchers to produce healthy and functional engineered cells rapidly, maintaining their health and functionality. By combining continuous fluid flow with electric fields, Kytopen enhances the efficiency of payload delivery to primary cells, supporting advancements in biology and paving the way for innovative cell and gene therapies.

Antelliq is the world’s leading animal intelligence group, providing world-class devices for animal identification and tracability, pioneering monitoring solutions, and delivering cloud and smart data products and services. The group has been active in this industry for over 60 years and currently employ over 1,900 people worldwide. It satisfies customer needs in over 100 countries. Antelliq supports farmers by providing real-time actionable information to help them manage their herds. it provides pet owners with smart devices and data that give them a better understanding of their pets’ activity and health needs, enriching relationships. it helps conservationists safeguard natural environments and wildlife. Underpinning the innovative and pioneering solutions are the Antelliq Innovation Centers. Around the globe our teams of engineers work to transform vision into reality. Leveraging decades of R&D experience across many markets, technologies and species, along with development environments and strict qualification procedures, we’re always inventing new ways to look after the health and well-being of animals. We bring together talented and experienced designers from many fields and professions in each of our Innovation Centres. The versatility and extensive know how of our interdisciplinary team enables us to make the most of state-of-the-art technologies and development methodologies. Our four Innovation Centers located around the world each have expertise in distinct areas, together providing a global approach to Antelliq innovation. • Netanya, Israel – Advanced multi-disciplinary monitoring solutions across different species • Vitre, France – Identification, tissue sampling and RFID reading technologies for livestock • Cambridge, UK – Connected devices and accessories for pet owners • Boise, US – Electronic identification technology for the fish and wildlife markets, and other natural resource conservation communities

ClearDATA is a healthcare-focused company that provides a cloud computing platform and information security services specifically designed to protect sensitive health data. Headquartered in Austin, Texas, ClearDATA offers a HITRUST-certified cloud that ensures compliance and security for healthcare organizations using major public cloud platforms. Their comprehensive suite of solutions includes cloud security posture management, managed detection and response services, and a robust Business Associate Agreement (BAA), making it a trusted partner for organizations aiming to safeguard patient information. By enhancing data management and mitigating privacy risks, ClearDATA empowers healthcare providers to optimize their IT infrastructure, ultimately improving healthcare delivery and outcomes.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Pelago, formerly known as Quit Genius, is a leading virtual clinic focused on substance use management, particularly for tobacco, alcohol, and opioids. The company aims to transform support for substance use by offering education, management skills, and opportunities for positive change to individuals struggling with addiction. Pelago provides employers with a means to offer on-demand, personalized support for employees seeking healthier lifestyles. Its platform utilizes cognitive behavioral therapy (CBT) to address the psychological aspects of addiction, helping users identify triggers and access support through animated videos, interactive exercises, and audio sessions. This approach allows individuals to work at their own pace with the assistance of a personalized coach. Pelago's services seamlessly integrate with health plans, pharmacy benefit managers, and wellness platforms, and the company has successfully supported over 750,000 members in managing their substance use and improving their overall well-being.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that focuses on providing integrated solutions for individuals with chronic conditions, particularly diabetes. Founded in 2008, Livongo combines advanced technology with personalized coaching to empower users in managing their health. Its platform includes cellular-connected devices and data-driven insights, facilitating real-time support for diabetes management while also addressing hypertension, prediabetes, weight management, and behavioral health. Livongo serves a diverse clientele, including employers, health plans, government entities, and labor unions, aiming to improve both clinical outcomes and user experience in chronic disease management. In 2020, Livongo became a subsidiary of Teladoc Health, further expanding its reach in the healthcare market.

Viralytics Limited is an Australian biotechnology company dedicated to the development and commercialization of oncolytic immunotherapies aimed at treating various types of cancer. The company's leading product, CAVATAK, is a proprietary formulation of a common cold virus currently undergoing Phase Ib clinical trials for melanoma, lung, and bladder cancer, and is in Phase II trials for late-stage melanoma. Additionally, CAVATAK is being explored in preclinical studies for several other cancers, including prostate, breast, and pancreatic cancer. Viralytics is also working on another product, EVATAK, targeting ovarian, prostate, and gastric cancers. With headquarters in Sydney and research operations in Newcastle, the company utilizes the cancer-destroying properties of benign viruses to enhance treatment effectiveness and minimize side effects. Formerly known as Psiron Ltd., Viralytics changed its name in December 2006 and now operates as a subsidiary of Merck & Co. Inc.

electroCore, Inc. is a commercial stage medical device company based in Basking Ridge, New Jersey, specializing in bioelectronic medicine. The company develops and markets non-invasive vagus nerve stimulation (nVNS) therapies aimed at improving patient outcomes in neurology. Its lead product, gammaCore, is a prescription-only device designed for the acute treatment of pain associated with migraines and episodic cluster headaches in adults, as well as for the preventative treatment of these conditions. The gammaCore system is a rechargeable and reloadable handheld device that is prescribed for multi-year use. The company has received FDA clearance for the use of gammaCore in various indications, including adjunctive treatment options for adults suffering from cluster headaches and migraines.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

PatientSafe Solutions, located in San Diego, California, specializes in innovative mobile solutions for point-of-care healthcare delivery. The company's flagship product, the PatientTouch System, enhances the productivity and safety of care teams by streamlining workflows on a single handheld device. This wireless clinical mobility solution integrates various functionalities, including positive patient identification, care interventions, and real-time communication, which are essential for improving patient safety and clinical outcomes. The PatientTouch System is designed with hospital-grade durability and features a high-performance barcode scanner, a full-shift battery, and an intuitive interface, making it suitable for frontline clinicians. By consolidating communication and workflows, PatientSafe Solutions enables hospitals to minimize harm, reduce waste, and enhance overall productivity in care delivery. The company's contributions to healthcare technology have garnered recognition, including being listed among the top venture-backed healthcare companies.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Serimmune Inc. is a biotechnology company focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014 and based in Goleta, California, the company utilizes its serum epitope repertoire analysis (SERA) technology platform, which integrates bacterial display peptide libraries, sequencing, machine learning, and custom bioinformatics. This platform enables the comprehensive profiling of antibody repertoires and the identification of antigens and epitopes linked to various health conditions, including infections, allergens, microbiome organisms, autoimmune diseases, and cancers. By decoding the human immune response, Serimmune aims to empower the creation of innovative diagnostics, vaccines, and therapeutic solutions.

ClearDATA is a healthcare-focused company that provides a cloud computing platform and information security services specifically designed to protect sensitive health data. Headquartered in Austin, Texas, ClearDATA offers a HITRUST-certified cloud that ensures compliance and security for healthcare organizations using major public cloud platforms. Their comprehensive suite of solutions includes cloud security posture management, managed detection and response services, and a robust Business Associate Agreement (BAA), making it a trusted partner for organizations aiming to safeguard patient information. By enhancing data management and mitigating privacy risks, ClearDATA empowers healthcare providers to optimize their IT infrastructure, ultimately improving healthcare delivery and outcomes.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that focuses on providing integrated solutions for individuals with chronic conditions, particularly diabetes. Founded in 2008, Livongo combines advanced technology with personalized coaching to empower users in managing their health. Its platform includes cellular-connected devices and data-driven insights, facilitating real-time support for diabetes management while also addressing hypertension, prediabetes, weight management, and behavioral health. Livongo serves a diverse clientele, including employers, health plans, government entities, and labor unions, aiming to improve both clinical outcomes and user experience in chronic disease management. In 2020, Livongo became a subsidiary of Teladoc Health, further expanding its reach in the healthcare market.